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Abstract 
 
Background 
Misuse of gammahydroxybutrate (GHB) and its prodrugs gammabutyrolactone (GBL) and 1,4 butanediol (1,4-BD) 
has increased greatly since the early 1990s, particularly amongst lesbian, gay, bisexual and transgender (LGBT) 
individuals in recreational and sexual settings, e.g. ‘chemsex’.  
Objective and method 
This paper presents an overview of GHB pharmacotoxicology and provides analyses of cases in the LGBT 
population associated with use of these substances extracted from the UK’s National Programme on Substance 
Abuse Deaths database, to which notification is voluntary.  
Results 
From 1995 to September 2013, 21 GHB/GBL-associated fatalities were reported. None involved 1,4-BD. Typical 
victims were: Male (100%); White (67%), young (mean age 34 years); employed (90%); with a drug misuse history 
(81%). Most deaths were accidental (67%) or related to recreational drug use (19%), the remaining (potential) 
suicides. The majority of fatalities (83%) occurred in private residences, typically following recreational use; others 
occurred in specific ‘gay’-oriented locales including clubs and saunas. Three London boroughs accounted for 62% of 
all notified deaths, reflecting the concentration of both resident and visiting ‘gay’ individuals. However, this may be 
an artefact of the voluntary nature of the data submission procedure in particular areas. GHB/GBL alone was 
implicated in 10% of fatalities. The following substances were implicated either alone or in combination in the 
remaining cases (percentages may add to more than 100%):  cocaine (38%); alcohol (33%); amphetamines (29%); 
ecstasy (29%); diazepam (24%); ketamine (24%); mephedrone (24%). Post-mortem blood levels: mean 660 (range 
22 - 2335; S.D. 726) mg/L.  
Conclusions 
Significant caution is needed when ingesting GHB/GBL, particularly with alcohol, benzodiazepines, stimulants, and 
ketamine. Risk of death is increased due to their CNS-depressant properties. Of these, ‘chemsex’ drugs such as 
cocaine, mephedrone and ketamine are of note. More awareness is needed in the ‘gay’ community about risks 
associated with the consumption of such substances. 
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Deaths in the Lesbian, Gay, Bisexual and Transgender community in the United Kingdom associated with 
GHB and precursors 
 
1. INTRODUCTION 
 
Gammahydroxybutyrate (GHB) is an endogenous chemical found in the human body. The protonated form is 
gammahydroxybutyric acid, whereas the deprotonated form of the carboxylic acid moiety is gammahydroxybutyrate 
[1, 2]. GHB is also known as sodium oxybate, sodium 4-hydroxybutyrate, and 4-Hydroxy-n-butyric acid. It can also 
be easily synthesised from readily obtainable ingredients. GHB’s prodrugs gammabutyrolactone (GBL; 
dihydrofuran-2(3H)-one) and 1,4 butanediol (1,4-BD; BDO) are easily converted into GHB in the body [3, 4]. 
 
The misuse of GHB and these prodrugs increased greatly in Western countries from the early 1990s, especially in the 
club and dance scenes [1, 5]. The period since has been marked by a rising number of deaths in the United States of 
America (USA), United Kingdom (UK), Western Europe, Australasia, and other developed countries [6-9].   
 
The purpose of this paper is to place in the public domain detailed particulars of fatalities associated with GHB and 
its prodrugs within the Lesbian, Gay, Bisexual and Transgender (LGBT) community in the UK. It highlights the 
dangers associated with its consumption, especially with regard to recreational and sexual uses. It also contributes to 
the pool of knowledge being built up on this drug.   
 
 
2. OVERVIEW OF GHB/GBL PHARMACOTOXICOLOGY 
 
GHB chemistry and pharmacology, metabolism and pharmacokinetics, medical uses, addiction potential, routes of 
administration, effects, hospital presentations, and a detailed analysis of all GHB/GBL deaths notified in the UK up 
to September 2013 have been previously reported [9, 10].  
 
2.1. Chemistry and pharmacology 
 
GHB is a natural substance found in the human central nervous system (CNS) as a degradation product of the 
neurotransmitter gamma-aminobutyric acid (GABA) and other organs including the liver, kidney, heart, bones as 
well as in brown fat [11]. Like GABA, GHB possesses distinct excitatory properties which may be due to its effect 
on the mesolimbic dopaminergic system [2, 4]. It can be metabolised in vivo to GABA and trans-4-hydroxycrotonic 
acid (THCA); the first of these being pharmacologically active at GABAB receptors [12] and the second one binds to 
the GHB receptor with a four-fold higher affinity than GHB [13]. Absorption of large amounts of GHB desensitises 
GHB receptors [14] which, along with direct stimulation of GABAB receptors by the molecule, results in GABA, 
dopamine and opiate release. This process is likely to be responsible for exogenous GHB’s recreational effects.  
 
GBL, a naturally occurring lactone precursor, is readily and irreversibly metabolised to GHB by peripheral 
lactonases [15]. 1,4 Butanediol is a naturally occurring aliphatic alcohol (dihydroxy) precursor of GHB [16]. Both of 
these prodrugs or precursors can be synthesised in vitro and in vivo into GHB [12, 15-23], and are readily available 
as industrial solvents.  
 
2.2. Metabolism and pharmacokinetics 
 
Following its exogenous (oral) ingestion, GHB is rapidly absorbed from the gastro-intestinal tract; time to peak is 
20-60 min [24]. Its elimination half-life is 27 min, proceeding in a dose-dependent saturable manner [24]. The 
percentage of GHB eliminated unchanged in urine is only 2-5% [25-27]. The dosage-response curve for GHB is 
steep. Time to peak concentration for 1,4-BD is about 25 min [28]. 
 
GBL is rapidly metabolised to GHB by non-enzymatic hydrolysis or by peripheral calcium dependent serum 
lactonases [29-31]; the half-life of this conversion is considered to be < 1 min [32]. Time to peak serum 
concentration of the molecule is 36-57 min, with the half-life of elimination being 30-52 min [33, 34]. GBL is 
regarded as more potent than GHB due to its more rapid absorption and greater bioavailability [35]. 
 
1,4-BD is subject to a two-stage in vivo conversion process in the liver via enzymatic biotransformation to gamma-
hydroxy butyraldehyde by alcohol dehydrogenase (ADH) and then by aldehyde dehydrogenase to GHB [12, 20, 23, 
35-37]. Its elimination half-life is 39 ± 11 min, suggesting its effects last longer than those of GHB [38]. There is a 
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common metabolic pathway for 1,4-BD and ethanol, leading to potential interactions between them [19, 36]. These 
substances also have a synergistic effect [39, 40], as there is between ethanol and GHB in respect of synergistic 
sedative effects [39, 41].  
 
2.3. Addiction potential   
 
GHB induces several psychopharmacological effects. Its acute effects include: euphoria, ataxia, confusion, 
hallucinations, anxiolysis, amnaesia, sedation/hypnosis, loss of consciousness, and anaesthesia [27, 42-45].  
 
Tolerance develops to GHB and its prodrugs’ effects in rodents [46-48] and humans. It is suggested that GHB is both 
physically and psychologically addictive [49], and has a high abuse potential. Cross-tolerance may exist between 
GHB and alcohol [7]. 
 
Dependence on GHB and its precursors is more are likely to develop amongst chronic users [50, 51]. Withdrawal 
syndrome is observed with GHB [52, 53], GBL/GHB [54], and GBL and 1,4-BD [8, 55-57]. It is characterised by 
insomnia, muscular cramps, tremors and anxiety. Symptoms appear within a few fours of the last dose taken, 
becoming severe by 24 h [58]. 
 
GHB was added to Schedule IV of the 1971 UN Convention on Psychotropic Substances on 29 March 2001. It 
became controlled in the UK under the Misuse of Drugs Act 1971 as a Class C drug on 1 July 2003; and also became 
a substance listed under Schedule 4 Part I of the Misuse of Drugs Regulations 2001. From 23 December 2009, GBL 
and 1,4-BD became Class C drugs, under Schedule 2, where they are intended for human consumption.  
 
2.4. Non-medical uses of GHB and its prodrugs  
 
GHB was first sold as a dietary supplement, and by the late 1980s was marketed in the USA as a steroid replacement 
for body-builders and weight lifters. Its use as an appetite suppressant has also been noted [1]. GHB’s more recent 
primary mode of abuse worldwide has been for its subjective (empathogenic), hypnotic, euphoric, disinhibitive and 
potentially hallucinogenic effects [59]. Illicit users of GHB/GBL report their subjective effects as comparable to 
alcohol [46], MDMA/ ‘ecstasy’ [60], and flunitrazepam [49].  
 
GHB and its prodrugs are often used recreationally with other substances [61, 62], including alcohol, cannabis, and 
stimulants (ecstasy/ Methylenedioxymethylamphetamine (MDMA), cocaine, amphetamine/”ice”), sildenafil [54, 63-
67]. Many GHB users employ MDMA to extend GHB’s effects [65, 68].  GHB and its derivatives are more likely to 
be used in private settings rather than in public night-life settings [64]. 
 
2.5. Use in the UK ‘gay’ community 
 
The molecule first appeared on the UK dance and club scenes during the spring of 1994, initially in 'gay' circles 
before spreading to other populations [9]. A survey in July 2010 of clients in “gay friendly” dance clubs in south 
London found that GHB and GBL were used relatively more often than in other types of venue [69]. Lifetime use of 
these molecules was 34% and 27%, with last year use being 22% and 24% respectively. These patterns were echoed 
in a survey conducted in London during July-September 2011 of genito-urinary clinics attendees which found higher 
rates of lifetime and previous month use of both GHB and GBL by gay men than by heterosexual males. Lifetime 
use of GHB and GBL amongst gay men was 22.7% and 16.1% respectively. Previous month rates were 2.4% and 
3.1% [70]. Lifetime use of GHB/GBL amongst gay males in south London between August 2013 and March 2014 
was found to be 30.6%, with 10.5% using in the previous four weeks [71], contrasting with 1.6% elsewhere in 
England [71, 72].  
 
Although GHB’s use as an aphrodisiac has been advocated in both heterosexual and homosexual markets [73], it is 
used particularly in the latter community, including bi-sexuals [74], due to its ability to boost energy and increase 
libido [75], enhance sex [64], assist relaxation (muscles) and promote increased confidence [71], and to facilitate 
sex-work and ‘chemsex’ [54]. Other perceived benefits include: sexual disinhibition [63, 74-80]; heightened sense of 
touch (tactility) [63, 64, 76, 77, 79]; more intense orgasms (especially amongst males) [63, 64, 71, 75-77]; and 
enhancement of male erectile capacity [79]. It is postulated that the sexual arousal caused by GHB and its prodrugs is 
connected with their ability to decrease anxiety and increase disinhibition via GABAB receptor agonist actions [81]. It 
has also been suggested that such behavioural effects entail altered transmission of dopamine [82], oxytocin [83] and 
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neurosteroids [84].  Sharing GHB/GBL is common in the male ‘gay’ community between not only friends and 
partners, but also relative strangers in some settings, e.g. parties, clubs and saunas [71]. 
 
GHB, GBL and similar substances have also been linked to cases of so-called 'date-rape' (alleged sexual assault) 
reported by the media in the USA, Europe [85, 86] and the UK [87]. In four murders GHB was administered to the 
victims [88-90]. 
 
2.6. Availability, route of administration and dosage 
 
GHB typically exists as either the free acid or as the sodium base (sodium oxybate), and typically very pure in its 
solid form. GHB is soluble in water. It is usually sold as an odourless, clear, liquid with a salty taste; but can be 
found in powder or tablet form, and occasionally as a bright blue liquid (‘blue nitro’). Retailers are still easy to find 
on the Internet, together with recipes to prepare the compound [1, 7, 91]. Individuals also manufacture GHB 
themselves, being able to easily obtain legal supplies of the precursors/prodrugs [38].  
 
Commonly, GHB and its prodrugs are used orally. Powder is usually dissolved in water or other drinks prior to use 
[1]. Occasionally, capsules containing sodium oxybate are used [85]. Despite GHB being available as a salt or 
powder form, there are only occasional reports of nasal insufflation [77].  There are some reports of intravenous (IV) 
use [1], of “shafting” (insertion into the rectum), and of “shelving” (insertion into the vagina) [92].  
 
In one study, the median quantity of GHB used orally by recreational users was 3 ml in a typical session and 4 ml in 
a heavy session [93]. Depending upon tolerance levels, recreational doses vary according to the effects sought, 
ranging from 1-5g daily, 15-70 mg/kg for a 70 kg adult [93, 94]. Mean daily usage of 53 ml (median 40, range 5-
200) is reported in a group of patients (n=27) presenting to drug services during 2008-13 in Brighton & Hove (UK) 
with primary GHB/GBL dependence, with ‘top ups’ at 1 hr (41%) or 2 hr (44%) intervals [54]. Oral dosages 
suggested by users are: 0.5g for relaxation and disinhibition, 1g for euphoric effects, and 2-3 g for deep sleep [95-
97]. Issues can occur due to inter-person variability in effects [98], the choice of correct dosage or taking doses too 
close together [1]. In addition, variation in the GHB concentrations in solutions, as well as pre-prepared ones, can 
give rise to some of the dangers associated with illicit use [94, 99, 100]. GHB 40 ml (3-9 doses) could hold a dose of 
as little as 3 g or a potentially toxic one of 20 g [101]. These factors mean an increased risk because of GHB’s 
narrow therapeutic window and steep dose-response association [102]. The GBL oral dose range is typically 1-3 ml, 
with user fora suggesting taking initial doses of 1.5-2 ml with a follow-up dose of 1 ml between 30 to 60 mins later 
[103]. Suggested dosages are: “a good relaxing/mood enhancing” 0.5-1 ml; “f**k you up” 1.5-2 ml; and “knock you 
out” 3 ml, based on a conversion rate of 1 ml pure GBL = 1.65 g GHB [103-105]. 
 
2.7. Effects  
  
Initial feelings after ingestion are euphoria and calmness, and then intoxication [106]. A low to moderate oral dose of 
10 mg/kg (0.75 g) can lead to short-term amnaesia and hypotonia, lowered inhibitions and increased libido. A high 
dose of 20-30 mg/kg (1.5-2.5 g) produces drowsiness and sleep, and can generate dizziness and confusion, muscle 
stiffness, nausea and vomiting. Very high doses of 50-70 mg/kg (4-5 g) can cause convulsions [107], amnaesia, 
hypotonia, and coma; it may also cause bradycardia and enhance cardiopulmonary depression. Doses in excess of 70 
mg/kg (5 g) can cause cardio-respiratory collapse [57, 99]. A potentially lethal dose of GHB ranges from 15-50 g 
(250-750 mg/kg) [60], with the effects of GHB being exacerbated by use with alcohol and other drugs, especially 
sedatives [1]. Loss of consciousness for short periods during sex after using GHB/GBL appears to be common and is 
considered “relatively normal” [71].  
 
2.8. Hospital presentations 
 
The growing recreational use of GHB has led to increased numbers of admissions to emergency departments (EDs) 
and calls to poisons centres in the EU [9]. One central London ED, whose catchment area includes a “substantial” 
‘gay’ club scene, recorded 158 GHB/GBL presentations in 2006 [108] and 270 in 2010 [109]; with most 
presentations having involved males aged 20-34 [70]. Only 34% reported having used GHB/GBL alone; other 
combinations included alcohol (34%), MDMA (32%) and ketamine (22%). A 2013-14 survey of European hospitals, 
including the UK, found GHB/GBL was the fourth highest substance responsible for acute ED drug toxicity 
presentation [110].  
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EDs receive patients with a variety of states, ranging from initial confusion, dizziness or euphoria, to vomiting and 
collapse, through to loss of consciousness or even coma, and hypothermia [1, 111-113]. 
 
2.9. Fatalities 
 
One measure of the risks inherent in the misuse of GHB and its prodrugs is deaths associated with their use. Our 
2015 paper [9] analysed data on 159 UK deaths.  This present paper focuses on a sub-set of these cases; those related 
to members of the LGBT community. This is because they appear to be disproportionately represented in the wider 
study. 
 
3. METHODS OF DATA COLLECTION AND ANALYSIS  
 
3.1. National Programme on Substance Abuse Deaths (NPSAD) 
 
NPSAD regularly receives information from coroners on a voluntary basis on deaths related to drugs in both addicts 
and non-addicts in England and Wales, Northern Ireland, the Channel Islands and the Isle of Man. Between 2004 and 
2011 information was also received from the Scottish Crime and Drug Enforcement Agency; data from the General 
Register Office for Northern Ireland has also been received since 2004. Since 1997 details of about 32,000 deaths 
have been received. To be recorded in the NPSAD database as a drug-related death, at least one of the following 
criteria must be met: (a) presence of one or more psychoactive substances directly implicated in death; (b) history of 
dependence or abuse of drugs; and (c) presence of controlled drugs at post-mortem. Ethical approval is not required 
in the UK for studies whose subjects are deceased, and solely involves retrospective reviews of death records.  
 
3.2. Case identification 
 
A range of documents are contained in coronial inquest files, although the variety differs from case to case. 
Typically, the Coroner has access to: statements from witnesses, family and friends; General Practitioner records (if 
the deceased is registered with one); reports from ambulance, police or other emergency services; hospital EDs and 
clinical ward reports; psychiatric and substance abuse team reports; as well as post-mortem and toxicology reports.   
 
For the main study [9] a retrospective study design was employed to identify relevant cases associated with the use 
of GHB, GBL and 1,4-BD by searching the NPSAD database with the following terms - 'GHB', 'GBH', ‘GBL’, ‘1,4-
BD’, ‘BDO’, 'gamma hydroxybutyrate', ‘gamma butyrolactone’ and 'sodium oxybate', and any variants in spelling. 
The fields searched on the database were those holding data on - drugs present at post-mortem, cause(s) of death, 
verdict, accident details, and 'other relevant information'. For this paper, information on sexual orientation was found 
in Coroners’ records, e.g. known to have a male partner, engaged in homosexual activities around time of death, etc. 
Such information was typically found in police reports, witness statements from partners, families, friends, etc. 
Details of the cases analysed here are given in the supplementary material published with our main study [9]. These 
cases were extracted based on this additional information, which was flagged in the main study. 
 
For further details regarding the interpretation of toxicological levels and toxicological screening for GHB and its 
prodrugs see the main study [9]. All cases reported here have either confirmatory evidence of GHB, GBL, etc. 
ingestion and/or the tissue levels are consistent with exogenous intake/misuse. 
 
3.3. Data analysis 
 
Data entry and analysis were performed using IBM® SPSS™ Statistics for Windows version 19 employing 
descriptive statistics. Data on blood, urine GHB/GBL concentrations are presented as mean, minimum, maximum, 
and standard deviation based on all cases with valid data for the variables used.  
 
4. RESULTS  
 
4.1. Number of deaths 
 
A total of 21 fatalities that met the above inclusion criteria were identified on the NPSAD database as having been 
reported by September 2013. The first reported death in the UK amongst the LGBT community related to GHB/GBL 
consumption occurred in 2001. GHB was consumed in just over half of cases (n=11), the remainder involved GBL 
ingestion; there were none attributed to the taking of 1,4-BD. The highest number of deaths occurred in the period 
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2006-8 (12 cases) with one or two cases occurring in subsequent years. (However, at least nine further deaths have 
occurred in the period 2011-5 and are detailed in the Discussion section.) 
 
4.2. Socio-demographics of decedents 
 
All decedents were male: 81.0% confirmed as homosexual, 9.5% as suspected homosexuals and 9.5% (two cases) 
reported as being both transgender and transvestite. Mean age was 34.4 (range 21.1 – 52.6) years (Table 1); 95% 
were aged less than 45 years. Where information was available, the decedents’ main characteristics were: White 
ethnicity 82.4%; UK-born 61.1%; in employment 89.5%; two-thirds were living with someone else; 81.3% had 
previously used drugs or had been dependent on them; one-third had used GHB/GBL. 
 
Information on prescribed psychoactive medications was available for only four cases.  One case was on diazepam 
and fluoxetine. A second case received sodium valproate. A third case was on a course of testosterone. The final 
(Attention Deficit Hyperactivity Disorder) case was prescribed: haloperidol, modafinil, dexamphetamine, 
amphetamine, clonazepam and gabapentin. 
 
Table 1: Socio-demographics of UK deaths in the LGBT community associated with GHB/GBL reported to 
NPSAD by September 2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Category Number (%) 
   
Total  21 (100.0) 
   
Gender Male 21 (100.0) 
Sexual orientation Confirmed homosexual 17 (81.0) 
 Suspected homosexual 2 (9.5) 
 Transgender & transvestite 2 (9.5) 
Country of birth England 10 (47.6) 
 Scotland 1 (4.8) 
 other European countries 2 (9.5) 
 Africa 3 (14.3) 
 Asia 1 (4.8) 
 Australia 1 (4.8) 
 Not known 3 (14.3) 
Employment status Unemployed 1 (4.8) 
 Employed manual 4 (19.0) 
 Employed non-manual 13 (61.9) 
 Student 1 (4.8) 
 Not known 2 (9.5) 
Living arrangements Alone 6 (28.6) 
 With others 12 (57.1) 
 Not known 3 (14.3) 
Ethnicity White 14 (66.7) 
 Chinese 1 (4.8) 
 Other 2 (9.5) 
 Not known 4 (19.0) 
History of any drug use Yes 13 (61.9) 
 No 3(14.3) 
 Not known 5 (23.8) 
    of which, history of 
GHB/GBL use 
Yes 7 (33.3) 
 No 0 (0.0) 
 Not known 14 (66.7) 
Injecting status Yes 1 (4.8) 
 No 8 (38.1) 
 Not known 12 (57.1) 
Age-group (years) 15-24 1 (4.8) 
 25-34 12 (57.1) 
 35-44 7 (33.3) 
 45-54 1 (4.8) 
Age at death (years) Male Mean 34.37; Min 21.07, Max 52.57, SD 7.33 
 7 
4.3. Circumstances of death 
 
All of the deaths reported to NPSAD occurred in England (19) and Scotland (2). Of note is that three-quarters 
(76.2%) of all cases occurred in Greater London, including 61.9% in the three London Boroughs of Lambeth, 
Southwark and Westminster. The peak number of deaths occurred between 2006 and 2009, with another peak in 
2012. Where known, the majority (66.7%) of cases died at home or in another private residence (friend’s or relative’s 
home), and 33.3% in hospital (Table 2). The manner of death in most cases was accidental (85.7%), with 14.3% 
being regarded as undetermined. This closely reflects the verdicts of coroners or other formal determinations, where 
accidental/misadventure verdicts were given in 66.7% of cases; along with non-dependent abuse of drugs (19.0%); 
and possible suicides for the remaining cases (14.3%). Deaths were proportionately (38.1%) more likely to occur on 
Saturday than on a week-day or Sunday. 
 
4.4. Events leading to death 
 
In at least four cases GHB was sourced from the Internet, as well as one case of GBL. In line with two-thirds of the 
deaths occurring at home, four-fifths (83.3%) of the events leading to such events also occurred at the home of the 
deceased or the home of another person. In many instances, such deaths followed recreational use of GHB/GBL in 
these settings. A range of other locations witnessed GHB consumption including LGBT-oriented pubs/clubs and 
other venues, including saunas (Table 2). 
 
 Table 2: Circumstances of UK deaths in the LGBT community associated with GHB/GBL reported to 
NPSAD by September 2013. 
 
 
Variable Category Number (%) 
Total  21 (100.0) 
   
Circumstances of death/events leading to death Recreational drug use/party - at home 5 (23.8) 
 Recreational drug use/party - other private residence 1 (4.8) 
 Recreational drug use/party - pub/club 4 (19.0) 
 Recreational drug use/party  gay-oriented health spa 2 (9.5) 
 Body-building/ fitness 3 (14.3) 
 Accidentally mistaken for water 1 (4.8) 
 In sexual activity 3 (14.3) 
 Open verdict 1 (4.8) 
 Not known 4 (19.0) 
Location of events leading to death Home 13 (62.0) 
 Other specified place 5 (23.8) 
 Of which, friends/relative’s home 1 (4.8) 
     Third party’s home 1 (4.8) 
     Hotel 1 (4.8) 
     Gay-oriented health spa 2 (9.5) 
 Not known 3 (14.3) 
Place of death At home 11 (52.4) 
 Private residential address 3 (14.3) 
 Hotel 1 (4.8) 
 Hospital 5 (23.8) 
 Gay sauna 1 (4.8) 
Verdict (conclusion) Accident/Misadventure 14 (66.7) 
 Open/Undetermined 3 (14.3) 
 Non-dependent abuse of drugs 4 (19.0) 
Manner of death Accidental 18 (85.7) 
 Undetermined 3 (14.3) 
Form of GHB consumed GHB 11 (52.4) 
 GBL 10 (47.6 ) 
Day of death Sunday 2 (9.5) 
 Monday 3 (14.3) 
 Tuesday 3 (14.3) 
 Wednesday 1 (4.8) 
 Thursday 2 (9.5) 
 Friday 2 (9.5) 
 Saturday 8 (38.1) 
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GHB/GBL consumption was not always for recreational purposes. For example, three cases used it for body-
building/fitness, and at least three cases to enhance sexual experiences. Whilst there were three cases of probable 
suicide where GHB/GBL was deliberately consumed so as to apparently cause death, some deaths were ‘accidental’ 
in the widest sense of the term, e.g. being mistaken for water. 
 
4.5. Cause of death 
 
When considering the underlying cause of death (Table 3), the majority of deaths were attributed to accidental 
poisoning (76.2%) and poisoning of undetermined intent (14.3%). There were other deaths where natural causes 
played a role as a consequence of taking GHB/GBL and other substances. The principal causes in this category were: 
cardio-respiratory (14.3%); cardiac (9.5%); and respiratory (4.8%). It may well be that the cardio-respiratory effects 
resulted from GHB/GBL ingestion. 
 
Table 3: Proximal and Underlying cause of deaths in the LGBT community associated with GHB/GBL 
reported to NPSAD by September 2013. 
 
ICD-10 
code 
Description Proximal 
cause 
Underlying 
cause 
  Number (%) Number (%) 
Mental & behavioural disorders due to psychoactive substance use 
F19.2 Multiple drug use - dependence 1 (4.8) 1 (4.8) 
Accidental poisoning by and exposure to 
X41 Anti-epileptic, sedative-hypnotic, anti-Parkinsonism and psychotropic drugs, not 
elsewhere classified 
10 (47.6) 16 (76.2) 
X44 Other and unspecified drugs, medicaments and biological substances 2 (9.5) 0 (0.0) 
Poisoning by and exposure to - of undetermined intent 
Y11 Anti-epileptic, sedative-hypnotic, anti-Parkinsonism and psychotropic drugs, not 
elsewhere classified 
2 (9.5) 3 (14.3) 
Other causes 
I26.9 Pulmonary embolism without mention of cor pulmonale 1 (4.8) 1 (4.8) 
I50.9 Heart failure, unspecified 2 (9.5) 0 (0.0) 
R09.2 Respiratory arrest 3 (14.3) 0 (0.0) 
    
All codes   21 (100.0) 21 (100.0) 
 
4.6. Post-mortem toxicology 
 
Although GHB was detected in all 21 cases, quantifiable blood concentrations of GHB were available in only 18 
(85.7%) (Table 4). The mean blood level was 659.8 (range 22-2355; S.D. 726) mg/L (Table 4). Urine levels were 
available for six cases (28.6%). The mean urine level for cases was 1139.8 (range (144-3000; S.D. 945.8) mg/L. 
 
The commonest groups of substances found, apart from GHB/GBL, were: alcohol; stimulants (cocaine, 
amphetamine/methylamphetamine, MDMA/MDA, mephedrone); benzodiazepines (principally diazepam); and 
ketamine (Table 4). There was a mean of 3.8 (range 1-9, SD 1.97) post-mortem substances, reflecting polysubstance 
use. The range of substance types listed above were also evident in the most common combinations reported: 
GHB/GBL and stimulant (28.6%); GHB/GBL and stimulant and ketamine (14.3%); GHB/GBL and stimulants and 
alcohol (9.5%); and GHB/GBL and alcohol (9.5%). GHB on its own was only found in one case. 
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Table 4: Post-mortem blood and urine levels in deaths in the LGBT community associated with GHB/GBL 
reported to NPSAD by September 2013 
 
Case number Drug(s) present at pm, with levels 
1 GHB 
2 GHB bl 270mg/L ur 824mg/L; cocaine bl 1.6mg/L; benzodiazepines, other bl diazepam 0.12mg/L desmethyldiazepam 
0.14mg/L temazepam 0.01mg/L; alcohol bl 47mg/100ml; methylamphetamine 0.02mg/L 
3 GHB 22mg/L; alcohol 15 mg/100ml; u:10mg; amphetamine 0.3 ug/L; heroin 0.16mg/L; diazepam <0.02mg/L; 
phenobarbitone. Other drugs at pm: gabapentin, ibuprofen 
4 MDMA bl 7.69 ug/ml; MDA bl 0.09ug/ml; GHB bl 800 mg/L; methylamphetamine bl 0.28ug/ml; amphetamine bl 0.11ug/ml; 
temazepam bl high therapeutic level  
5 Alcohol <10 mg/100ml; ecstasy AM bl 0.46ug/ml PM 0.02ug/ml ur + AM bl MDA +; GHB PM bl 42mg/L 
6 MDMA bl 0.60ug/ml; MDA: 0.07ug/ml; Ketamine bl 0.59 ug/ml; cocaine +; GHB bl 200 mg/L  
7 GHB bl 530ug/ml; alcohol bl 79mg/100ml, ur 148mg/100ml; cocaine bl & ur + consistent with recreational use; Cocaethylene 
+  
8 MDMA bl 0.31ug/ml ur +; MDA bl 0.2ug/ml ur +; methylamphetamine ur +; cocaine ur +; GHB bl 508mg/L  
9 GHB; cocaine; ecstasy  
10 GHB bl 311ug/ml ur 3000ug/ml  
11 GHB bl 77mg/L; Ketamine 0.05mg/L; cocaine 0.14mg/L  
12 Alcohol 263 mg/100ml: Flox urine: 309 ug/ml; GHB bl: 245 ug/ml   
13 Amphetamine bl 0.08mg/L; cocaine bl benzoylecgonine 1.24mg/L; GHB bl 1348mg/L; MDMA bl 0.46mg/L  
14 GHB bl 648ug/ml; Ketamine bl 1.61ug/ml; methylamphetamine bl 0.19ug/ml; ur +; amphetamine bl 0.02ug/ml; ur +; alcohol 
bl & ur <10mg/100ml  
15 Alcohol bl 156mg/dl ur  220mg/100ml VH 200mg/100ml; chlordiazepoxide bl 0.23mg/L; diazepam nordiazepam 0.38mg/L 
VH 0.14mg/L; GHB bl 520mg/L ur 1300mg/L  
16 Alcohol bl 230mg/dl; GHB bl 1400mg/L  
17 GBL bl 260ug/ml ur1300ug/ml VH 130ug/ml; Mephedrone bl 0.21ug/ml ur +; TFMPP - 3-Trifluoromethylphenylpiperazine 
monohydrochloride bl 0.02ug/ml ur +; methylamphetamine bl 0.04ug/ml ur +; Ketamine bl <0.01ug/ml ur +; diazepam bl 
<0.05ug/ml & metabs. pholcodine, zopiclone, carboxy-THC also in PM. 
18 Mephedrone bl 0.12mg/L; GHB bl 474mg/L ur 1442mg/L; cocaine metabolites ur +. Hair analysis suggested had a history of 
use of mephedrone, MDMA and exposure to cocaine in 3 months prior to death. 
19 Alcohol bl >240mg/100ml; GHB; Mephedrone  
20 Mephedrone bl 0.13 mg/L; ur+; Normephedrone ur+; GHB + GBL bl 2335 mg/L; +GBL ur 1471 mg/L  
21 Alcohol bl 181mg/L; gammahydroxybutyrate (GHB) bl 2313mg/L; Ketamine bl 0.15mg/L; Mephedrone bl 0.12mg/L; 
diazepam bl diazepam 0.71mg/L, bl desmethyldiazepam 0.46mg/L, bl oxazepam 0.040mg/L, bl temazepam 0.11mg/L; 
fluoxetine bl 0.060mg/L  
Abbreviations AM = Ante Mortem; Carboxy-THC = 11-nor-9-carboxy-delta-9-THC; GBL = Gamma butyrolactone; GHB = 
Gammahydroxybutyrate; MDA = Methylenedioxyamphetamine; MDMA = Methylenedioxymethylamphetamine; PM = Post 
Mortem; VH = Vitreous humour 
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Table 5: Additional UK deaths involving GHB/GBL in the LGBT community reported in the media, 2012-6.   
 
Source Date Location Case details 
[114] 25 February 2012 
 
 
 
 
 
 
 
27 October 2012 
 
 
 
 
 
29 October 2012 
London 
Borough of 
Lambeth, 
England 
A 41 year-old Greek supervisor was found dead in a locked private room by the 
manager of a gay-oriented sauna after being alerted by a friend of the deceased who 
said he was unwell. First aid and CPR were administered. Police later found a bottle 
of GHB and a bag of white powder. The Coroner recorded a narrative verdict 
saying: “his death was drug related from a combination of mephedrone and GHB. 
There is no evidence the drugs were forcibly given to him and there is no evidence 
he tried to take his life.” 
 
A 41 year-old communications officer was found dead at 08:00 on a Saturday 
morning at the same gay sauna. PM toxicology indicated blood levels of GHB 
803mg/l (“enough for a fatality”), cocaine 0.13mg/L (“relatively high”), and alcohol 
(“mild levels”).The pathologist found that the deceased died as a result of GHB 
causing significant brain injury. 
 
A 46 year-old HIV+ security officer was found collapsed at the same time as the 
previous case at the same locus. He was taken to hospital but died two days later. 
PM toxicology revealed that GHB and MPA had been consumed. The pathologist 
concluded that GHB had caused significant brain injury and eventually pneumonia. 
[87, 115] 21 January 2013 Bristol, 
England 
Alcoholic homosexual aged 47 had consumed 2,5-Dimethoxy-4-chloroamphetamine 
(DOC) bought on the Internet by a third party convicted of assaulting him. 
Witnesses said the deceased had been acting strangely and danced on the sofa, later 
lying on the floor shaking in an uncomfortable position. At 05:30 when he had 
stopped breathing an ambulance was called but the crew were unable to save him. 
The pathologist was unable to ascertain the cause of death but GHB/GBL, DOC and 
alcohol (at nearly three times the UK limit for driving) were found in the deceased’s 
body. 
[88-90]  
 
 
 
 
 
 
 
19 June 2014 
 
20 August 2014 
 
 
20 September 2014 
 
20 September 2015 
East 
London, 
England 
A chef aged 40 is appearing in court at the time of writing (October 2016*) charged 
with 4 counts of murder and of administering a poison with intent to endanger life or 
inflict grievous bodily harm. He is alleged to have met his victims on gay websites, 
invited back to his house where he gave them GHB “within the range at which 
deaths from GHB intoxication have been reported”, before having sex with them 
whilst they were unconscious. After suffering overdoses in the early hours of the 
morning, the victims were dumped in or near a churchyard in east London. 
 
White fashion and design student aged 23. 
 
Artist from Slovakia aged 22. Inquest found he had GHB and methadone in his 
system. 
 
White aged 21. Inquest found he had GHB and methadone in his system. 
 
White forklift driver aged 25. 
[116] 10 November 2014 Manchester, 
England 
White, officer administrator, aged 22, with a history of drug use GHB and ketamine) 
at week-ends, as well as injecting mephedrone. Was on prescribed anti-depressants 
and hypnotic/sedatives to help come off the drugs. He died after taking GHB, 
mephedrone, ecstasy and ketamine during an all-night party in a private apartment. 
Moments before he died the decedent was seen crawling around a bed “making 
weird noises” before entering and leaving the bathroom saying he was feeling sick. 
He then collapsed in front of his partner. A post-mortem showed he died from 
multiple drug toxicity. The Coroner recorded a conclusion of ‘drug-related death’.  
[117-119] 20 January 2015 City of 
London, 
England 
Colombian-born 18 year-old café-worker, a regular drug user from age of 15. Had 
consumed GBL and mephedrone along with alcohol during an evening spent with 
his boyfriend and another male. When the boyfriend awoke the other individual had 
left, but the deceased was lying beside him in bed with blood and vomit round his 
mouth. Paramedics attended the scene and pronounced life extinct. The PM 
concluded that the deceased had died of a lethal combination of drugs including 
GBL and mephedrone. The police found glass containers with 482 ml of GBL and 
60 plastic bags containing 82 g of mephedrone, which had been purchased by the 
deceased’s boyfriend. He subsequently pleaded guilty to two counts of possession 
with intent to supply GBL and mephedrone for the all-night ‘chem-sex’ party. 
*Subsequently found guilty of all 4 offences 
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5. DISCUSSION  
 
5.1. Number of cases 
 
Since the first known death in the UK associated with the ingestion of GHB and its prodrugs in 1995, [120] there 
have been a minimum of 159 cases in which these substances were implicated up to September 2013 [9]. This paper 
examines in detail the 21 deaths of these related to the LGBT community. It is believed that this is the first paper to 
look at such cases within this sub-population of GHB/GBL users. 
 
Whilst the first death in this community occurred in 2001, there appears to have been two peaks, e.g. in 2006-8 and 
2012 onwards [121, 122]. The patterns described here do not reflect the effects of control of GHB in 2003 and GBL 
in 2009, suggesting that use of GHB/GBL within the UK LGBT community may be unaffected by the substances’ 
legal status. 
 
5.2. Socio-demographics 
 
At least two of the NPSAD cases were known to be both transgender and transvestite, a further case was a well-
known ‘drag-artist’, confirming previous reports [123]. The proportion of homosexual men in the general population 
of the UK is about 2.0% [124]. However, in some areas, such as Brighton & Hove, the LGBT community may 
account for as much as 15% of the local population; four-fifths of the GHB/GBL dependence sample in the area 
identified themselves as being from the LGBT community [54].  
 
All deaths notified to NPSAD by the end of September 2013, and the additional cases reported here, occurred in 
England and Scotland, although most cases appear to have occurred in specific south London areas, where there is a 
concentration of well-known gay clubs and gay-friendly saunas and gyms, bars and cafes. This led to a range of 
initiatives, including provision of materials on safer use of GHB/GBL [125, 126]; a ‘zero tolerance’ approach to the 
possession and use of drugs; presence in specific clubs of paramedics on duty [127].   
 
The mean age at death in this study was slightly higher and more concentrated (34.4, range 21.1 – 52.6 years) 
compared to those in all NPSAD GHB/GBL cases (32.1, range 18.9 – 60.1 years) during the same period. However, 
thus difference is not statistically significant (Mann-Whitney two-tailed U-test, Z-Score = -1.38358, p value = 
0.16758, p <0.05). This result is lower than the mean age of 46 years found for HIV+ MSM clients in the ASTRA 
study [123]. As with most reported GHB-related deaths in our main study [9], as well as in the USA and elsewhere, 
the cases detailed here mostly involved Caucasian/White individuals (82.4%, where known, of NPSAD cases).  
Where known, most victims (61.1%) were born in the UK compared to 77% of the main NPSAD study (Ratio of 
proportions two-tailed test, Z-Score = -1.4578, p = 0.1443, not significant at p <0.05) but there were also a number of 
individuals born elsewhere in Europe (11.1%) or on other continents, including 16.7% in Africa. This diversity is 
also reflected in the additional cases reported in Table 5.  Drug-use status was known for 16 cases, with 13 (81.3%) 
of these being known drug users. This proportion is higher than that (70.7%) of the main study, but not statistically 
significant (Ratio of proportions, two-tailed test, Z-Score = 0.9429, p-value = 0.34722, p <0.05). Only one decedent 
was known to be an injector compared to about 18% of those in the main study, also statistically non-significant 
(Ratio of proportions, two-tailed test, Z-Score = -1.1381, p-value = 0.25428, p< 0.05). This low rate of injecting is in 
line with that for gay males in England. [128] 
 
The temporal pattern of most GHB/GBL deaths occurring amongst this community on Saturday (38.1%) is much 
higher than for Saturday and Sunday combined (36%) in the main study [9], and compared to an expected proportion 
of 14.1%. This probably reflects higher consumption rates on Friday to Sunday, echoing findings for ED admissions 
in studies of GHB/GBL [101, 129-131]. 
 
5.3. Post-mortem toxicology and other findings 
 
Consistent with previous findings [9], post-mortem GHB blood concentrations found in this study sample range from 
22 to 2335 mg/L. GHB/GBL alone was identified at post-mortem in only two (9.5%) of these 21 cases compared to 
36.5% in the full study; this difference is statistically significant (Ratio of proportions, two-tailed test, Z-Score = -
2.4627, P-value = 0.0139, p <0.05). ONS figures for death registrations in England and Wales for 1993-2013 show 
that overall the proportion of GHB/GBL cases involving the drug without other drugs was 54.7%, and with alcohol 
36.7% [121]. The majority of cases here involved the ingestion of at least two (mostly three) other substances, 
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typically combinations of any of the following: alcohol; stimulants; diazepam; and ketamine, confirming previous 
findings [70, 132-135]  
 
Co-ingestion with other sedatives such as alcohol or ketamine increases the likelihood of intoxication [38], with the 
effects on respiratory depression of GHB/GBL [136] being enhanced by the presence of sedatives. Both alcohol and 
GHB are metabolised by alcohol dehydrogenase and potentiate the effects of each other [60, 137, 138], a finding 
confirmed in preclinical studies [139]. In the present study GHB was used with alcohol in 9.5% of cases; with other 
drugs in 61.9%; and with other drugs and alcohol in 19.0%. The consumption of GHB/GBL alone or with other CNS 
depressants led here to cardiac, respiratory and cardio-respiratory failure; these findings are consistent with those of 
previous reports [8, 9, 106, 140, 141]. 
 
Pre-existing medical conditions may have contributed to death or been exacerbated by the use of GHB/GBL in some 
cases; for example, bradycardia has long been recognised as a complication in the therapeutic use of GHB and also 
in those using it recreationally [106], whilst arrhythmias, or even cardiac arrest, have been described when the drug 
is ingested with cocaine [106] or mephedrone [142].  Furthermore, GHB has a potentially important synergistic 
interaction with PCP and ketamine, as they act as NMDA receptor antagonists [143].  
 
5.4. Limitations 
 
A number of limitations have to be considered here. Since analysis for the presence of GHB is not usually performed 
routinely in clinical or post-mortem investigations in the UK, the number of cases reported is likely to be an 
underestimation. Furthermore, given that GHB is metabolised relatively quickly in the body, it may not be present in 
toxicology screens, even if they are performed. Finally, GHB is also an endogenous compound. The total number of 
cases reported here by NPSAD is likely to be an under-estimate due to: (a) incomplete geographical coverage; (b) 
further cases awaiting the conclusion of formal investigations; (c) the voluntary nature of the NPSAD reporting 
system; (d) information on the sexual orientation and/or the settings/circumstances of death may be unknown to the 
Coroner and/or not noted in the information submitted to the Programme, etc. Whilst coverage by NPSAD of 
Coroners' jurisdictions is not complete, it has remained at a consistently high level over the past decade or more. 
Other sources of information were used, including media reports, so as to counter this limitation [9]. There is a lack 
of robust research information about some aspects of GHB/GBL use, e.g. dosage levels, and it has been necessary to 
use anecdotal reports by consumers. In addition, it has been necessary to include information from media sources in 
order to obtain a more complete picture regarding the context(s) of some aspects. Since those who die from GHB use 
appear to differ in a number of ways from 'typical' victims of drug-related deaths, it is possible that investigators may 
have missed other cases. These factors may mean that the cases reported here are a skewed sample and an 
underestimate of actual index deaths during this period.  
 
6. CONCLUSIONS 
 
Although the number of cases reported here is relatively small, this is still the most comprehensive and detailed 
report of fatalities associated with non-medical use of GHB and its derivatives in the LGBT community produced to 
date, both in respect of the UK and globally, although other evidence is emerging [144]. 
 
Medical practitioners and other health professionals need to be aware of the likelihood of coming across patients 
consuming GHB and related substances. Awareness of such issues needs to be highlighted to drug treatment 
services, sexual health services, and genito-urinary clinics catering for the LGBT community [145]. Finally, the 
dangers of mixing GHB/GBL with alcohol and/or other CNS-depressant substances needs to be better described in 
prevention campaigns, as well as cautioning users regarding the concomitant use of stimulants. 
 
ABBREVIATIONS  
1,4-BD  1,4 butanediol 
DEA  Drugs Enforcement Administration 
EMCDDA European Monitoring Centre for Drugs & Drug Addiction 
EMEA  European Medicines Agency 
GBL  Gammabutyrolactone 
GHB  Gammahydroxybutyrate 
MDA  Methylenedioxyamphetamine 
MDMA  Methylenedioxymethylamphetamine 
NPSAD  National Programme on Substance Abuse Deaths 
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 Graphical abstract 
 
Key characteristics of GHB/GBL deaths in the UK LGBT community 
 
Characteristic (N=21) 
Male 100.0% 
White 66.7% 
Employed 89.5% 
History of drug use 81.3% 
Age  mean 34.4; range 21.1-52.6; SD 
7.33 years 
Aged 25-44 years 90.5% 
Accidental manner of death 85.7% 
Underlying cause of death – accidental 
poisoning 
76.2% 
Death following recreational GHB/GBL use 70.6% 
Death occurring at private residential 
address 
66.7% 
Average number of drugs consumed 3.8 
Death locus in 3 London boroughs 61.9% 
Most common substances found in 
combination with GHB/GBL 
cocaine (38.1%); alcohol (33.3%); 
amphetamine/”ice” (28.6%); ecstasy 
(28.6%); diazepam (23.8%); 
ketamine (23.8%); mephedrone 
(23.8%) 
Post-mortem blood levels of GHB/GBL mean 659.8; range 22.0-2335.0; SD 
726.0 mg/L 
 
 
 
